Group 1 - The China Securities Regulatory Commission (CSRC) has requested Jiangyin Pharmaceutical to provide supplementary explanations regarding the compliance of its offshore structure and return acquisition [1] - Jiangyin Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 28, 2025, with Goldman Sachs, Haitong International, and HSBC as joint sponsors [1] - The CSRC has outlined specific areas for Jiangyin Pharmaceutical to clarify, including the regulatory procedures related to foreign exchange management, offshore investment, foreign investment, and tax management [1] Group 2 - Jiangyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies [2] - The company aims to innovate the current treatment standards for chronic diseases through the development of first-in-class and best-in-class siRNA therapies, supported by three major potential blockbuster product pipelines and a proprietary siRNA technology platform [2] - Jiangyin Pharmaceutical's strategy is built on a global collaboration network to address significant unmet medical needs [2]
靖因药业拟港股上市 中国证监会要求补充说明搭建离岸架构及返程并购的合规性等
Zhi Tong Cai Jing·2026-01-05 13:06